European Union - English - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd. - amlodipine, valsartan, hydrochlorothiazide - hypertension - angiotensin ii antagonists, plain, angiotensin ii antagonists, combinations - treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (hct), taken either as three single-component formulations or as a dual-component and a single-component formulation.

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd. - nateglinide - diabetes mellitus, type 2 - drugs used in diabetes - nateglinide is indicated for combination therapy with metformin in type 2 diabetic patients inadequately controlled despite a maximally tolerated dose of metformin alone.

Israel - English - Ministry of Health

novartis israel ltd - ruxolitinib as phosphate - tablets - ruxolitinib as phosphate 10 mg - ruxolitinib - * myelofibrosis (mf) jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. * polycythaemia vera (pv) jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.*graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies

Israel - English - Ministry of Health

novartis israel ltd - ruxolitinib as phosphate - tablets - ruxolitinib as phosphate 5 mg - ruxolitinib - ruxolitinib - * * myelofibrosis (mf) jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. * polycythaemia vera (pv) jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.*graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies

Israel - English - Ministry of Health

novartis israel ltd - ruxolitinib as phosphate - tablets - ruxolitinib as phosphate 15 mg - ruxolitinib - ruxolitinib - * myelofibrosis (mf) jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. * polycythaemia vera (pv) jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.*graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies

Israel - English - Ministry of Health

novartis israel ltd - ruxolitinib as phosphate - tablets - ruxolitinib as phosphate 20 mg - ruxolitinib - ruxolitinib - * myelofibrosis (mf) jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis. * polycythaemia vera (pv) jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.*graft versus host disease (gvhd)jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren, amlodipine, hydrochlorothiazide - hypertension - cardiovascular system - rasitrio is indicated for the treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of aliskiren, amlodipine and hydrochlorothiazide given concurrently at the same dose level as in the combination.

European Union - English - EMA (European Medicines Agency)

novartis europharm ltd - valsartan, amlodipine (as amlodipine besilate) - hypertension - agents acting on the renin-angiotensin system - treatment of essential hypertension.imprida is indicated in patients whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy.